Loading…
Lobbying Spend
—
Filings
2
Firms Hired
1
Active Period
2008
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Enhancing Drug Safety and Innovation Act of 2007
2008 · third_quarter · Firm: Polsinelli PC
S. 251 Pharmaceutical Market Access Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; S. 484 Enhancing Drug Safety and Innovation Act of 2007; H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007; H.R. 788 Food and Drug Administration Safety Act of 2007; H.R. 2117 Health Freedom Protection Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of 2007
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1561
S. 251 Pharmaceutical Market Access Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; S. 484 Enhancing Drug Safety and Innovation Act of 2007; H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007; H.R. 788 Food and Drug Administration Safety Act of 2007; H.R. 2117 Health Freedom Protection Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of 2007
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2117
Pharmaceutical Market Access and Drug Safety Act of 2007
2008 · third_quarter · Firm: Polsinelli PC
S. 251 Pharmaceutical Market Access Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; S. 484 Enhancing Drug Safety and Innovation Act of 2007; H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007; H.R. 788 Food and Drug Administration Safety Act of 2007; H.R. 2117 Health Freedom Protection Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of 2007
Client expense: — · Firm income: $20,000
Matched citations: H.R. 380
Food and Drug Administration Safety Act of 2007
2008 · third_quarter · Firm: Polsinelli PC
S. 251 Pharmaceutical Market Access Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; S. 484 Enhancing Drug Safety and Innovation Act of 2007; H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007; H.R. 788 Food and Drug Administration Safety Act of 2007; H.R. 2117 Health Freedom Protection Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of 2007
Client expense: — · Firm income: $20,000
Matched citations: H.R. 788
Pharmaceutical Market Access Act of 2007
2008 · third_quarter · Firm: Polsinelli PC
S. 251 Pharmaceutical Market Access Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; S. 484 Enhancing Drug Safety and Innovation Act of 2007; H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007; H.R. 788 Food and Drug Administration Safety Act of 2007; H.R. 2117 Health Freedom Protection Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of 2007
Client expense: — · Firm income: $20,000
Matched citations: S. 251
Food and Drug Administration Safety Act of 2007
2008 · third_quarter · Firm: Polsinelli PC
S. 251 Pharmaceutical Market Access Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; S. 484 Enhancing Drug Safety and Innovation Act of 2007; H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007; H.R. 788 Food and Drug Administration Safety Act of 2007; H.R. 2117 Health Freedom Protection Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of 2007
Client expense: — · Firm income: $20,000
Matched citations: S. 468
Enhancing Drug Safety and Innovation Act of 2007
2008 · third_quarter · Firm: Polsinelli PC
S. 251 Pharmaceutical Market Access Act of 2007; S. 468 Food and Drug Administration Safety Act of 2007; S. 484 Enhancing Drug Safety and Innovation Act of 2007; H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007; H.R. 788 Food and Drug Administration Safety Act of 2007; H.R. 2117 Health Freedom Protection Act of 2007; H.R. 1561 Enhancing Drug Safety and Innovation Act of 2007
Client expense: — · Firm income: $20,000
Matched citations: S. 484
Source: Senate LDA